Abstract:Correction to: EMBO Mol Med (2021) 13: e12627. DOI https://doi.org/10.15252/emmm.202012627 ¦ Published online 13 January 2021 The authors were alerted to duplicated images between Figures 2A and 3G, 2B and 4I, and 4B and 4I. The authors state that the human IMA HE stainings in Figure 2A and Figure 3G are from the same sample. The legend of Figure 3G is amended to indicate that the sample is also shown in Figure 2A. The 10x HE image in Figure 2B had been incorrectly displayed in the 40x HE image in Figure 4I. The authors state that they used the incorrect photograph from the KLN IMA vehicle treatment group in Figure 2B. The authors have identified the correct low-magnification image that corresponds to the magnification currently displayed in Figure 2B and herewith retract and replace this panel. The bottom middle panel of NICD immunostaining for KLN IMA in Figure 4B displayed an image from a similar field of the NICD immunostaining for KLN IMA (vehicle group) in Figure 4I. The authors state that these two photographs were mislabeled during the acquisition process. The authors have identified the correct image for NICD immunostaining for KLN IMA in Figure 4B in the original data and herewith retract and replace this panel. Lastly, the authors note that the labeling in Figure 4J had previously been inverted and this is herewith corrected. The authors state that these changes do not affect the interpretation of the data or the conclusions of the study. The authors apologize for this oversight and for any inconvenience it may have caused. Figure 2B. Original. Figure 2B. Corrected. Figure 4B. Original. Figure 4B. Corrected. Figure 4J. Original. Figure 4J. Corrected.

Corrigendum to “inhibition of IGF1R Enhances 2-Deoxyglucose in the Treatment of Non-Small Cell Lung Cancer” [lung Cancer 123 (2018) 36–43]

Correction: Corrigendum: Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model

Corrigendum: NDRG1 Inhibition Sensitizes Osteosarcoma Cells to Combretastatin A-4 Through Targeting Autophagy

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Corrigendum to ‘silencing KIF18B Enhances Radiosensitivity: Identification of a Promising Therapeutic Target in Sarcoma’ [ebiomedicine 61 (2020) 103,056]

[Corrigendum] Inhibition of sphingosine-1-phosphate phosphatase 1 promotes cancer cells migration in gastric cancer: Clinical implications.

Corrigendum to “blocking the Glycolytic Pathway Sensitizes Breast Cancer to Sonodynamic Therapy” [ultrasound Med Biol 44 (2018) 1233-1243].

Erratum to: Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway

Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors Via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

[Corrigendum] The role of IGFBP‑5 in mediating the anti‑proliferation effect of tetrandrine in human colon cancer cells

Corrigendum to "long Non-Coding RNA LINC-01572:28 Inhibits Granulosa Cell Growth Via a Decrease in P27 (kip1) Degradation in Patients with Polycystic Ovary Syndrome" [ebiomedicine 36 (2018) 526-538].

Erratum: Glycolysis Gatekeeper PDK1 Reprograms Breast Cancer Stem Cells under Hypoxia

RETRACTED ARTICLE: Long Non-Coding RNA 91H Regulates IGF2 Expression by Interacting with IGF2BP2 and Promotes Tumorigenesis in Colorectal Cancer

[Corrigendum] High glucose and high insulin conditions promote MCF‑7 cell proliferation and invasion by upregulating IRS1 and activating the Ras/Raf/ERK pathway

Nanog Maintains Stemness of Lkb1‐deficient Lung Adenocarcinoma and Prevents Gastric Differentiation

[Corrigendum] High Expression of FUSE Binding Protein 1 in Breast Cancer Stimulates Cell Proliferation and Diminishes Drug Sensitivity

[Corrigendum] The cranberry flavonoids PAC DP‑9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells

Correction: Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum